The misfolding of normal proteins and their subsequent aggregation in the brain is characteristic of a group of related neurologic diseases, the "protein conformational disorders", including Parkinson disease, Alzheimer disease, and the transmissible spongiform encephalopathies (TSEs) (1 ) . The development of highly sensitive and specific diagnostic assays for these diseases is a high priority as effective therapies become available or as food safety regulations mandate the removal of infected animals from the food chain.
Current test development effort in the TSE field has been focused mainly on designing screening tests for the aggregated prion proteins in bovine, ovine, and cervid brain tissue. Several immunoassays for bovine spongiform encephalopathy (BSE) have been evaluated by the European Union (EU) (2 ) , and three are now approved for routine use in testing laboratories. Those approved include two ELISAs in the microplate format and reagents for a Western blot analysis. The abnormal, or rogue, prion protein detected by these tests is considered to be the best indicator of TSE infection (2 ) , but the anti-prion protein antibodies used in these assays cannot distinguish the normal, globular, proteinase K-sensitive (␣-helix-rich) form of the prion protein (PrP sen ) from the abnormal, aggregated, and relatively proteinase K-resistant form (PrP res ), in which the secondary structure is dominated by ␤-sheet. Thus, a complex sample preparation procedure is required to eliminate the normal prion protein in the brain homogenate before immunoassay, usually involving a proteinase K digestion step carried out under closely controlled conditions. Under-or overdigestion problems with the protease step can compromise the specificity and sensitivity of the subsequent immunoassay.
A further complication in the current TSE test procedures is a requirement for a PrP res denaturation step, after protease digestion of the brain homogenate, to expose the appropriate epitopes in the protein for binding by the currently available monoclonal antibodies used in the assays. Clearly the availability of an antibody with specificity for the rogue prion protein in its native state would be a major advantage in assay development, but although there have been reports of such antibodies (3 ) , as yet there are no reagents or assays commercially available.
As an alternative to seeking PrP res -specific antibodies, we have been screening synthetic polymeric ligands to identify compounds with specificity for the native conformation of the rogue prion protein. The recombinant prion protein (produced in Escherichia coli) has binding sites for heparan and related polyanions (4 ) . Other polyanions (such as pentosan polysulfate) and polycationic dendrimers reduce concentrations of PrP res produced by TSEinfected cell lines (5, 6 ) , although the nature of the interaction between the abnormal aggregated form of the protein and the polyions is currently unknown.
We have identified several polymeric compounds (designated as the "Seprion" ligands) that, under the appropriate reaction conditions, have the ability to bind the PrP res present in BSE, scrapie, chronic wasting disease, and Creutzfeldt-Jakob disease-infected brain tissue with high selectivity in the presence of a large excess of the normal PrP sen form (7 ) . The mechanism of binding of PrP res to the Seprion ligands is unclear at this stage because information is currently not available on the detailed structure of the protein aggregates, although the optimal ligands were found to be of high molecular mass (Ͼ50 000 Da), presumably facilitating multiple ionic interactions with the aggregated protein structure (which would be expected to have multiple repeating regions of positive or negative charge). The Seprion ligands are mixed-mode in character and predominantly polyionic, but they are also able to bind strongly to solid-phase materials in a simple procedure suited to large-scale manufacturing processes. One polyionic ligand (designated v2) was chosen for inclusion in a BSE test development program.
The BSE assay was performed as described by Lane et al. (7 ) and is illustrated schematically in Fig. 1A . Briefly, 200 mg of bovine brain tissue (taken from the obex region) was homogenized in a ribolyser (four 30-s disruptions, with cooling in ice for 60 s between steps), and 100 L of the homogenate was then added directly to the wells of a Seprion v2-coated microplate and incubated for 2 h. After capture of PrP res , the wells were washed, and the prion protein was denatured on the surface for 10 min by a standard chemical method, followed by an additional wash to remove denaturant. One hundred microliters of a commercially available prion protein-specific monoclonal antibody/peroxidase conjugate was then added and incubated for 60 min. After removal of excess conjugate, 100 L of 3,3Ј,5,5Ј-tetramethylbenzidine substrate was added and incubated for 30 min. After the reaction was stopped, the absorbance at 450 nm was measured.
Shown in Fig. 1B are the results obtained with the Seprion immunometric assay from a panel of UK-derived bovine brain samples obtained from 26 animals (supplied by the TSE Archive, Veterinary Laboratories Agency, Weybridge, UK). The presence of BSE infection was confirmed in 11 animals by observation of the characteristic pathology in the brain and also by an immunohistochemistry procedure. Fig. 1B also includes data obtained from the same sample set with an EU-approved ELISA assay that uses a proteinase K digestion, a denaturation step (by boiling), and a centrifugation procedure to concentrate the abnormal prion protein before detection in a standard, microplate-based immunometric procedure.
Both test procedures correctly identified the positive BSE-infected samples, and the negative noninfected brain tissue gave only a background signal value in the Seprion immunometric assay. In additional experiments, the
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Seprion immunometric assay achieved 100% specificity with Ͼ100 negative brain tissue homogenates tested (data not shown). Dilution curves prepared with positive brain homogenate dispersed in negative brain material have indicated that the Seprion assay has a detection limit comparable to that of the EU-approved ELISA (data not shown).
In summary we have identified polyionic compounds that, under the appropriate reaction conditions, exhibit high specificity for the rogue form of the prion protein present in the brain of BSE-infected animals. The Seprion immunometric assay procedure, using enzyme-conjugated antibodies of appropriate specificity, can eliminate the complex and potentially variable proteinase K sample preparation step currently used in TSE screening tests. On the limited number of samples tested to date, the Seprion immunometric assay has a sensitivity and specificity comparable to those of an EU-approved ELISA, with the additional advantage that the assay procedure is ideally suited to automation on standard ELISA processor instrumentation. Further investigation on a larger number of infected animals will be needed to determine whether the Seprion immunometric assay could be useful in the routine detection of TSEs. We have recently prepared magnetic microparticles coated with the Seprion ligands, and studies are underway on the capture of the abnormal prion protein from larger quantities of brain homogenate, urine, and blood from animals infected with scrapie. 
RAMP
® (Rapid Analyte Measurement Platform) is a platform technology that can be adapted to quantify immunologically active substances. The system consists of two components: a disposable test cartridge that houses an analyte-specific immunochromatographic nitrocellulose membrane strip and a portable scanning fluorescence reader that quantifies antibody-antigen complexes. The unique feature of the RAMP technology is that an internal control is run and measured concurrently in every assay, allowing the system to compensate for inherent test-totest and reader-to-reader variations (1 ) .
In the RAMP System, the test sample is delivered into the sample well of a RAMP test cartridge and the cartridge is inserted into the reader. As the sample migrates along the strip, fluorescently dyed latex particles conjugated to analyte-specific antibodies bind to antigen, if present in the sample. Antigen-bound particles are immobilized at the detection zone by specific antibodies, and some of the excess particles are immobilized at the internal control zone by anti-immunoglobulin antibodies. On completion of the test, the reader measures fluorescence (F-units) emitted by the complexes bound at the detection and internal control zones and calculates a ratio between these measurements.
Immunochromatographic assays are dynamic in nature. In these tests the sample is in contact with the immobilized capture antibodies for only a short time; therefore, the degree of antibody-antigen binding is subject to variability. For any fixed amount of free antigen, the captured signal will increase with longer contact time. This contact time is affected by such factors as capillary speed, sample viscosity, humidity, and temperature (2) (3) (4) . Nitrocellulose membranes differ in structure, wetting characteristics, and surface quality. These variations can occur both within and between lots and can cause large discrepancies in the test results (5 ). In the RAMP System, the detection and internal control zones are positioned in close proximity to each other on the nitrocellulose strip; therefore, factors that affect the binding of particles at the detection zone similarly affect binding at the internal control zone. A ratio of the measurement at these two zones, the RAMP ratio, then corrects for variations in binding.
Fluorescence-based assays are generally difficult to operate quantitatively because of a lack of stable fluorescent standards for instrument standardization (6, 7 ) . In addition, the detection of fluorescent signal is affected by differences in instrument optical configurations, filtering, and excitation light wavelength and intensity. The RAMP ratio factors out the absolute units of fluorescence through the ratio calculation itself; the ratio is a relative value of the measurement of signal at the detection zone divided by the sum of the detection zone and the internal control zone. The signal intensity can vary within the linear range of the instrument and not change the ratio. With the ratio, the readers do not require routine recalibration; this is an important feature for point-of-care testing devices (8 ) .
The RAMP reader and the RAMP myoglobin assay have been cleared for sale by the US Food and Drug Administration and the Canadian Therapeutic Products Directorate. Additional RAMP tests have been developed for use in both clinical and environmental applications. To demonstrate the broad application of this technology with effective correction for test-to-test variation of binding at the detection zone, we prepared samples containing different amounts of each of six different analytes over their respective diagnostically relevant ranges. Serial dilutions of solutions or suspensions of each of the analytes, including three environmental agents (Bacillus anthracis, botulinum toxin, and ricin) and three cardiac markers [myoglobin, creatine kinase-MB (CK-MB), and troponin I] were prepared, and aliquots were tested using the corresponding RAMP test. Triplicates of each dilution were tested for the first three, and replicates of five were tested for each dilution of cardiac markers. A 70-L aliquot of each sample was appropriately diluted and delivered into the sample well of a RAMP test cartridge, and the cartridge was inserted into the reader. The mean, SD, and CV were calculated for the binding of each dilution at each of the two zones. The corresponding RAMP ratio was calculated for each dilution, and the CV of these ratios, as well as the mean CV across the analyte range, are reported in Table 1. A comparison of the reproducibility of test results for each analyte was made between the binding of particles at the detection zone only and the RAMP ratio. In all cases there was an improvement in the mean CV for test results across the analyte ranges tested when the RAMP ratio was used. The CV of Bacillus anthracis test results was improved twofold, from 7.5%, using detection-zone-binding only, to 3.8% when internal control zone binding was used to calculate the RAMP ratio. Likewise, the mean CV for botulinum toxin and ricin test results were improved 2.2-fold and 1.6-fold, respectively. Similarly, for the cardiac markers the mean CV for myoglobin, CK-MB, and troponin I test results were improved 5.7-fold, 2.3-fold, and 2.2-fold, respectively.
The RAMP ratio was shown to correct for even large variability in binding of latex particles at the detection zone. For example, data from five replicates of 50 g/L myoglobin showed extreme differences in binding at the detection zone (CV ϭ 35%). The replicates with the highest fluorescence measured at the detection zone also showed the highest fluorescence measured at the internal control zone. The RAMP ratio calculated with measure- 
